Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma

This study is currently recruiting participants.

This phase I trial studies the side effects and best dose of anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570 in treating patients with peripheral T-cell lymphoma follicular variant or angioimmunblastic T-cell lymphoma that has returned after a period of improvement (relapsed) or has not responded to previous treatment (refractory). Monoclonal antibodies, such as MEDI-570, may block cancer growth in different ways by targeting certain cells.

Study Type:  Interventional

Study Design:  

Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment

Official Title:  A Phase I Evaluation/Dose Escalation of MEDI-570 in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma (PTCL) Follicular Variant and Angioimmunoblastic T-Cell Lymphoma (AITL)

Conditions:  

Follicular Variant Peripheral T-Cell Lymphoma
Recurrent Angioimmunoblastic T-cell Lymphoma
Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma
Refractory Angioimmunoblastic T-cell Lymphoma
Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma

Interventions:  

Biological: Anti-ICOS Monoclonal Antibody MEDI-570
Other: Laboratory Biomarker Analysis
Other: Pharmacological Study

Phase:  Phase 1

External Link:  https://clinicaltrials.gov/ct2/show/NCT02520791